A new drug that slows the pace of Alzheimer’s disease is too expensive for too little benefit to be used on the NHS, the drugs spending watchdog says. Donanemab was hailed as a turning point in the disease last year. But the National Institute of Health and Care Excellence (NICE) said the drug provided only … Read more
A leading charity says the NHS is unprepared for the rollout of innovative new drugs. Source link
The antibody treatment donanemab slows clinical decline by around a third, a large trial confirms. Source link
March 15, 2021 — An experimental drug appeared to slow cognitive decline in people with early Alzheimer’s disease, according to newly published research. The drug, donanemab, is an antibody that targets and removes plaques from the brain called amyloid-beta, which are thought to play a role in Alzheimer’s disease. Compared to people in the study … Read more